Minerva Neurosciences (NERV) Amortizatization of Intangibles (2014 - 2026)
Minerva Neurosciences' (NERV) quarterly Amortizatization of Intangibles came in at $136741.0 in Q1 2026, up 3112.14% on a QoQ basis from $4257.0 in Q3 2024.
Powered by 
Analysis
Minerva Neurosciences (NERV) Amortizatization of Intangibles (2014 - 2026) Analysis & Trends
Minerva Neurosciences (NERV) has 12 years of Amortizatization of Intangibles data on file, last reported at $136741.0 in Q1 2026.
- Quarterly Amortizatization of Intangibles changed N/A year-over-year to $136741.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $136741.0 (up 1184.92% YoY) and the FY2024 annual result came in at $17027.0, down 33.33% from the prior year.
- Amortizatization of Intangibles improved to $136741.0 in Q1 2026, from $4257.0 in the prior quarter.
- In the past five years, Amortizatization of Intangibles ranged from a high of $136741.0 in Q1 2026 to a low of $4257.0 in Q3 2024.
- A 4-year average of $20632.6 and a median of $6385.0 in 2022 frame the typical range for Amortizatization of Intangibles.
- Annual changes were most pronounced in 2023 — Amortizatization of Intangibles changed 0.0% — and 2024, when it plunged 33.33%.
- Tracing NERV's Amortizatization of Intangibles over 4 years: stood at $6385.0 in 2022, then changed by 0.0% to $6385.0 in 2023, then sank by 33.33% to $4257.0 in 2024, then surged by 3112.14% to $136741.0 in 2026.
- The last three Amortizatization of Intangibles figures came in at $136741.0 (Q1 2026), $4257.0 (Q3 2024), and $6385.0 (Q2 2024), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Amortizatization of Intangibles (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | - |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | 4.33 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | - |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | - |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 678,000.00 |
| 10 | Minerva Neurosciences | 207.37 Mn | 207.37 Mn | - | 397,733.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 397,733.00 |
| Mar 31, 2026 | 136,741.00 |
| Sep 30, 2024 | 4,257.00 |
| Jun 30, 2024 | 6,385.00 |
| Mar 31, 2024 | 6,385.00 |
| Dec 31, 2023 | 6,385.00 |
| Sep 30, 2023 | 6,385.00 |
| Jun 30, 2023 | 6,385.00 |
| Mar 31, 2023 | 6,385.00 |
| Dec 31, 2022 | 6,385.00 |
| Sep 30, 2021 | 14,939.00 |
| Jun 30, 2021 | 44,014.00 |
| Mar 31, 2021 | 42,833.00 |
| Dec 31, 2020 | 41,679.00 |
| Sep 30, 2020 | 40,555.00 |
| Jun 30, 2020 | 39,483.00 |
| Mar 31, 2020 | 38,449.00 |
| Dec 31, 2019 | 37,440.00 |
| Mar 31, 2019 | 34,622.00 |
| Sep 30, 2018 | 1,000.00 |